Nucleic acids encoding antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease
AssigneeThe USA, as represented by the Secretary, Dept. of Health and Human Services
InventorsRichard M. Siegel, Francoise Meylan, Yun-Jeong Song
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.
Claims9
A nucleic acid encoding a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TL1A comprising a nucleic acid that encodes an immunoglobulin heavy chain comprising the variable region amino acid sequence set forth in SEQ ID NO:
- 34 and an immunoglobulin light chain comprising the variable region amino acid sequence set forth in SEQ ID NO:
- 42.
A nucleic acid encoding a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TL1A comprising the nucleic acid sequences of SEQ ID NO:
- 35, SEQ ID NO:37, and SEQ ID NO:
- 39, and the nucleic acid sequences of SEQ ID NO:
- 3, SEQ ID NO:
- 45, and SEQ ID NO:
- 47.
Dependencies are inferred from the claim text.